Influence of tirofiban application on myocardial injury and platelet activation in patients with STEMI during PCI
Yan Shilin
Luo Yongbai
Zhu Haofeng
Xu Chao
Wu Meng
Abstract：Objective To investigate the influence of tirofiban application on myocardial injury and platelet activation in patients with STEMI during PCI. Methods STEMI patients (n=90) were chosen from Yangling Demonstration Zone Hospital from Dec. 2014 to Feb. 2017, and randomly divided into control group and tirofiban group (each n=45). The control group was given routine PCI, and tirofiban group was given PCI combined with tirofiban with 10 μg/kg as the first dose and 0.15 μg/(kg·min) as maintain dose. The difference in myocardial injury markers including cardiac troponin I (cTnI), creatine kinase-MB isoenzyme (CK-MB) and B-type natriuretic peptide (BNP), and platelet function indexes including P-selectin, von Willebrand factor (vWF), platelet-derived growth factor BB (PDGF-BB) and platelet distribution width (PDW) were compared between 2 groups after PCI for 24 h. Results The baseline data including sex and age had no significant difference between 2 groups (P>0.05). After PCI for 24 h, the content of serum cTnI, CK-MB and BNP were significantly lower in tirofiban group than those in control group (P<0.05). The levels of serum P-selectin, vWF, PDGF-BB and PDW were significantly lower in tirofiban group than those in control group (P<0.05). Conclusion PCI combined with tirofiban during the procedure can effectively relieve myocardial injury and inhibit platelet activation after PCI in STEMI patients.
Keywords：ST-segment elevation myocardial infarctionPercutaneous coronary interventionTirofibanMyocardial injuryPlatelet activation
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1325-1327,1331 )